Browse RUNX2

Summary
SymbolRUNX2
Namerunt-related transcription factor 2
Aliases AML3; PEBP2A1; PEBP2aA1; CCD; CBFA1; CBF-alpha-1; CLCD; PEA2aA; PEBP2aA; PEA2-alpha A; PEBP2-alpha A; SL3-3 ......
Chromosomal Location6p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00853 Runt domain
PF08504 Runx inhibition domain
Function

Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis (PubMed:28505335, PubMed:28738062, PubMed:28703881). Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters. In osteoblasts, supports transcription activation: synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE) (By similarity). Inhibits KAT6B-dependent transcriptional activation.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0001958 endochondral ossification
GO:0002051 osteoblast fate commitment
GO:0002062 chondrocyte differentiation
GO:0002063 chondrocyte development
GO:0002076 osteoblast development
GO:0002521 leukocyte differentiation
GO:0007159 leukocyte cell-cell adhesion
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007224 smoothened signaling pathway
GO:0008543 fibroblast growth factor receptor signaling pathway
GO:0008589 regulation of smoothened signaling pathway
GO:0021700 developmental maturation
GO:0030098 lymphocyte differentiation
GO:0030217 T cell differentiation
GO:0030278 regulation of ossification
GO:0030326 embryonic limb morphogenesis
GO:0030509 BMP signaling pathway
GO:0032330 regulation of chondrocyte differentiation
GO:0032332 positive regulation of chondrocyte differentiation
GO:0035107 appendage morphogenesis
GO:0035108 limb morphogenesis
GO:0035113 embryonic appendage morphogenesis
GO:0035115 embryonic forelimb morphogenesis
GO:0035136 forelimb morphogenesis
GO:0036075 replacement ossification
GO:0040036 regulation of fibroblast growth factor receptor signaling pathway
GO:0042110 T cell activation
GO:0042475 odontogenesis of dentin-containing tooth
GO:0042476 odontogenesis
GO:0042481 regulation of odontogenesis
GO:0042487 regulation of odontogenesis of dentin-containing tooth
GO:0044344 cellular response to fibroblast growth factor stimulus
GO:0045165 cell fate commitment
GO:0045667 regulation of osteoblast differentiation
GO:0045669 positive regulation of osteoblast differentiation
GO:0045778 positive regulation of ossification
GO:0045879 negative regulation of smoothened signaling pathway
GO:0048469 cell maturation
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048701 embryonic cranial skeleton morphogenesis
GO:0048704 embryonic skeletal system morphogenesis
GO:0048705 skeletal system morphogenesis
GO:0048706 embryonic skeletal system development
GO:0048736 appendage development
GO:0048863 stem cell differentiation
GO:0051216 cartilage development
GO:0060173 limb development
GO:0060348 bone development
GO:0060349 bone morphogenesis
GO:0060350 endochondral bone morphogenesis
GO:0061035 regulation of cartilage development
GO:0061036 positive regulation of cartilage development
GO:0061448 connective tissue development
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071593 lymphocyte aggregation
GO:0071772 response to BMP
GO:0071773 cellular response to BMP stimulus
GO:0071774 response to fibroblast growth factor
GO:0090287 regulation of cellular response to growth factor stimulus
GO:1901522 positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus
GO:1904888 cranial skeletal system development
GO:2000027 regulation of organ morphogenesis
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003682 chromatin binding
GO:0008134 transcription factor binding
GO:0043425 bHLH transcription factor binding
GO:0070491 repressing transcription factor binding
Cellular Component GO:0000785 chromatin
GO:0000790 nuclear chromatin
GO:0005667 transcription factor complex
GO:0044454 nuclear chromosome part
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-2032785: YAP1- and WWTR1 (TAZ)-stimulated gene expression
Summary
SymbolRUNX2
Namerunt-related transcription factor 2
Aliases AML3; PEBP2A1; PEBP2aA1; CCD; CBFA1; CBF-alpha-1; CLCD; PEA2aA; PEBP2aA; PEA2-alpha A; PEBP2-alpha A; SL3-3 ......
Chromosomal Location6p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RUNX2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolRUNX2
Namerunt-related transcription factor 2
Aliases AML3; PEBP2A1; PEBP2aA1; CCD; CBFA1; CBF-alpha-1; CLCD; PEA2aA; PEBP2aA; PEA2-alpha A; PEBP2-alpha A; SL3-3 ......
Chromosomal Location6p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RUNX2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRUNX2
Namerunt-related transcription factor 2
Aliases AML3; PEBP2A1; PEBP2aA1; CCD; CBFA1; CBF-alpha-1; CLCD; PEA2aA; PEBP2aA; PEA2-alpha A; PEBP2-alpha A; SL3-3 ......
Chromosomal Location6p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RUNX2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.3940.0203
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.790.226
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.0850.257
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0870.801
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1180.943
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0530.981
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.20.725
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4110.732
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.060.96
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.130.881
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.520.643
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2070.172
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RUNX2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.11.49.70.0589
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.11.79.40.0895
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRUNX2
Namerunt-related transcription factor 2
Aliases AML3; PEBP2A1; PEBP2aA1; CCD; CBFA1; CBF-alpha-1; CLCD; PEA2aA; PEBP2aA; PEA2-alpha A; PEBP2-alpha A; SL3-3 ......
Chromosomal Location6p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RUNX2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRUNX2
Namerunt-related transcription factor 2
Aliases AML3; PEBP2A1; PEBP2aA1; CCD; CBFA1; CBF-alpha-1; CLCD; PEA2aA; PEBP2aA; PEA2-alpha A; PEBP2-alpha A; SL3-3 ......
Chromosomal Location6p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RUNX2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RUNX2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRUNX2
Namerunt-related transcription factor 2
Aliases AML3; PEBP2A1; PEBP2aA1; CCD; CBFA1; CBF-alpha-1; CLCD; PEA2aA; PEBP2aA; PEA2-alpha A; PEBP2-alpha A; SL3-3 ......
Chromosomal Location6p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RUNX2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRUNX2
Namerunt-related transcription factor 2
Aliases AML3; PEBP2A1; PEBP2aA1; CCD; CBFA1; CBF-alpha-1; CLCD; PEA2aA; PEBP2aA; PEA2-alpha A; PEBP2-alpha A; SL3-3 ......
Chromosomal Location6p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RUNX2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRUNX2
Namerunt-related transcription factor 2
Aliases AML3; PEBP2A1; PEBP2aA1; CCD; CBFA1; CBF-alpha-1; CLCD; PEA2aA; PEBP2aA; PEA2-alpha A; PEBP2-alpha A; SL3-3 ......
Chromosomal Location6p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RUNX2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRUNX2
Namerunt-related transcription factor 2
Aliases AML3; PEBP2A1; PEBP2aA1; CCD; CBFA1; CBF-alpha-1; CLCD; PEA2aA; PEBP2aA; PEA2-alpha A; PEBP2-alpha A; SL3-3 ......
Chromosomal Location6p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RUNX2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.